CytoAgents

Executive Summary

CytoAgents is a clinical-stage biopharmaceutical company developing oral small molecule immunomodulators for cytokine-driven inflammatory conditions. Its lead candidate, CTO1681, targets Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), severe complications of CAR-T cell therapies and other immunotherapies. With an orally bioavailable mechanism poised to address an urgent unmet need, the company is currently in Phase 1 clinical trials. Beyond oncology, CytoAgents plans to expand into asthma, COPD, and atopic dermatitis, leveraging its platform to modulate inflammatory pathways across multiple indications. The company is privately held and headquartered in San Diego.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for CTO1681 in CRS/ICANS40% success
• Q2 2027IND submission or approval for a second indication (e.g., asthma)50% success
• H1 2027Partnership or licensing deal for CTO1681 with a larger pharma30% success